French preventive healthcare startup Lucis raises €7.2 million from General Catalyst, Y Combinator, others | EU-Startups

French preventive healthcare startup Lucis has announced the closing of a €7.2 million ($8.5 million) Seed funding round to boost its European expansion, broaden its network of partner laboratories and physicians, and scale its platform. 

The round was led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co, and North South Ventures.

Maxime Berthelot, CEO and co-founder of Lucis, said, “Our mission is to empower individuals to take ownership of their health by giving them a clear view of key indicators before symptoms even appear, and providing practical guidance to improve their well-being, without replacing physicians.

“At a time when more and more Europeans are looking to take control of their health and feel better overall, this funding round will allow us to democratise access to disease prevention by connecting analyses conducted in certified laboratories, medical expertise, and a simple, user-friendly platform.”

Founded in 2025 in Paris by Maxime Berthelot, Baptiste Debever, and Max Gueroi, Lucis offers preventive health check-ups carried out in certified laboratories and interpreted by a medical team with the support of AI. It claims to deliver a clear, structured view of more than 180 biomarkers, including cardiometabolic health, hormones, inflammation, liver and kidney function, as well as certain micronutrients. 

It positions itself strictly as a preventive tool for individuals and not as a medical platform. It emphasises that users should not consider its services as a replacement for medical consultation, diagnosis, or prescription.

According to the company, rather than delivering results in a static PDF format, each member gains access to a clear dashboard and a prioritised action plan built around five pillars: nutrition, supplements, physical activity, sleep/recovery, and mental health.

Lucis has already conducted more than 500,000 clinical tests in its initial markets, which include France, the United Kingdom, Ireland, and Portugal.